title: Choroidal detachment after an uneventful intravitreal injection.
abstract: OBJECTIVE
  The purpose of this report was to describe a case of choroidal detachment after an uneventful intravitreal injection using a 30-gauge needle.
  
  
  METHODS
  An 88-year-old patient with acute onset of neovascular age-related macular degeneration developed a choroidal detachment after an uneventful intravitreal injection in the infero-temporal aspect of the fundus.
  
  
  RESULTS
  The patient described no symptoms related to the chorioretinal detachment. Additional intravitreal injections were required to treat an active subfoveal choroidal neovascularization. These injections were placed at the contralateral side in the supero-nasal quadrant. She was closely watched on a 2-week follow-up schedule. The choroidal detachment remained asymptomatic for the patient and resolved spontaneously, and the best corrected visual acuity improved from 0.2 to 0.63 during a 6-month follow-up. A mild hyperpigmentation remained at this location.
  
  
  CONCLUSIONS
  Asymptomatic choroidal detachments may occur after intravitreal injection. Although treatment was not needed, additional injections should be avoided in the same quadrant until the detachment has resolved.
authors.affiliation: Department of Ophthalmology, University of Bonn, Bonn, Germany. meyer_eye@yahoo.com
authors.forename: Carsten H
authors.initials: CH
authors.lastname: Meyer
authors.forename: Christian K
authors.initials: CK
authors.lastname: Brinkmann
authors.forename: Hans-Martin
authors.initials: HM
authors.lastname: Helb
mesh_terms: D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015862:Choroid Diseases / Q000139:chemically induced*; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D007267:Injections; D008268:Macular Degeneration / Q000150:complications; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000139:chemically induced*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab